Clobazam: A Safe, Efficacious, and Newly Rediscovered Therapeutic for Epilepsy

CNS Neuroscience and Therapeutics

Volumn 21, Issue 7, 2015, Pages 543-548

  Gauthier, Angela C ^a   Mattson, Richard H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticonvulsants; Benzodiazepines; Clobazam; Epilepsy

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; PHENOBARBITAL; PHENYTOIN; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE;

ATAXIA; CLINICAL TRIAL (TOPIC); DIZZINESS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESISTANT EPILEPSY; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TOLERANCE; EPILEPSY; HUMAN; LENNOX GASTAUT SYNDROME; MONOTHERAPY; NONHUMAN; REVIEW; SEDATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME; DRUG DEVELOPMENT;

ANTICONVULSANTS; BENZODIAZEPINES; DRUG DISCOVERY; EPILEPSY; HUMANS;

EID: 84931566907     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12399     Document Type: Review

References (61)

1. Thurman DJ, Beghi E, Begley CE, et al. Standards for epidemiologic studies and surveillance of epilepsy. Epilepsia 2011;52(Suppl 7):2-26.
2. Kwon O-Y, Park S-P. Depression and anxiety in people with epilepsy. J Clin Neurol 2014;10:175-188.
3. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-319.
4. Mattson R, Cramer J, Collins J, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-151.
5. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: Evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47:1094-1120.
6. Sternbach LH. The Benzodiazepine Story. In: Priest RG, Filho UV, Amrein R, et al., editors. Benzodiazepines today and tomorrow. Netherlands: Springer, 1980;5-17.
7. Baenninger A, Alberto Costa e Silva J, Hindmarch I, Moeller HJ, Rickels K. Good chemistry: the life and legacy of valium inventor Leo Sternbach. New York: McGraw-Hill, 2004.
8. Shorvon SD. Antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs, 4th edn. New York: Raven Press, 1995;763-777.
9. Sankar R. GABA(A) receptor physiology and its relationship to the mechanism of action of the 1, 5-benzodiazepine clobazam. CNS Drugs 2012;26:229-244.
10. Wheless JW, Phelps SJ. Clobazam: A newly approved but well-established drug for the treatment of intractable epilepsy syndromes. J Child Neurol 2013;28:219-229.
11. Giarratano M, Standley K, Benbadis SR. Clobazam for treatment of epilepsy. Expert Opin Pharmacother 2012;13:227-233.
12. Ng Y, Collins SD. Clobazam. Neurotherapeutics 2007;4:138-144.
13. Doi T, Ueda Y, Tokumaru J, Willmore LJ. Molecular regulation of glutamate and GABA transporter proteins by clobazam during epileptogenesis in Fe(+++)-induced epileptic rats. Brain Res Mol Brain Res 2005;142:91-96.
14. Kasugai Y, Swinny JD, Roberts JDB, et al. Quantitative localisation of synaptic and extrasynaptic GABAA receptor subunits on hippocampal pyramidal cells by freeze-fracture replica immunolabelling. Eur J Neurosci 2010;32:1868-1888.
15. 1-GABA(A)-receptor complexes. PLoS ONE 2014;9:e88456.
16. Rupp W, Badian M, Christ O, et al. Pharmacokinetics of single and multiple doses of clobazam in humans. Br J Clin Pharmacol 1979;7(Suppl 1):51S-57S.
17. Volz M, Christ O, Kellner HM, et al. Kinetics and metabolism of clobazam in animals and man. Br J Clin Pharmacol 1979;7(Suppl 1):41S-50S.
18. Lundbeck [Internet]. ONFI (clobazam) prescribing information; 2011 [cited 2014 August 6]. Available from: www.lundbeck.com.
19. Brogden RN, Heel RC, Speight TM, Avery GS. Clobazam: A review of its pharmacological properties and therapeutic use in anxiety. Drugs 1980;20:161-178.
20. Giraud C, Tran A, Rey E, et al. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: Importance of CYP2C19. Drug Metab Dispos 2004;32:1279-1286.
21. Walzer M, Bekersky I, Blum RA, Tolbert D. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy 2012;32:340-353.
22. Kosaki K, Tamura K, Sato R, et al. A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev 2004;26:530-534.
23. Sennoune S, Mesdjian E, Bonneton J, et al. Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. Ther Drug Monit 1992;14:269-274.
24. Allen JW, Oxley J, Robertson MM, et al. Clobazam as adjunctive treatment in refractory epilepsy. Br Med J (Clin Res Ed) 1983;286:1246-1247.
25. Keene DL, Whiting S, Humphreys P. Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Can J Neurol Sci 1990;17:317-319.
26. Renfroe J, Conry J, Ng Y, et al. Effects of concomitant lamotrigine or valproate therapy on clobazam for lennox-gastaut syndrome: subanalyses of the CONTAIN Trial. Neurology 2012;78. P06.120.
27. Weintraub D, Buchsbaum R, Resor SR, Hirsch LJ. Effect of antiepileptic drug comedication on lamotrigine clearance. Arch Neurol 2005;62:1432-1436.
28. Yamamoto Y, Takahashi Y, Imai K, et al. Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy. Eur J Clin Pharmacol 2014;70:1203-1210.
29. Bun H, Monjanel-Mouterde S, Noel F, et al. Effects of age and antiepileptic drugs on plasma levels and kinetics of clobazam and N-desmethylclobazam. Pharmacol Toxicol 1990;67:136-140.
30. Koeppen D, Baruzzi A, Capozza M, et al. Clobazam in therapy-resistant patients with partial epilepsy: A double-blind placebo-controlled crossover study. Epilepsia 1987;28:495-506.
31. Montenegro MA, Cendes F, Noronha AL, et al. Efficacy of clobazam as add-on therapy in patients with refractory partial epilepsy. Epilepsia 2001;42:539-542.
32. Kalra V, Seth R, Mishra D, Saha NC. Clobazam in refractory childhood epilepsy. Indian J Pediatr 2010;77:263-266.
33. Scott DF, Moffett A. The long-term effect of clobazam as adjunctive therapy in epilepsy. Acta Neurol Scand 1988;77:498-502.
34. Buchanan N. Clobazam in the treatment of epilepsy: Prospective follow-up to 8 years. J R Soc Med 1993;86:378-380.
35. Schmidt D. Benzodiazepines clinical efficacy and use in epilepsy. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic Drugs, 5th edn. Philadelphia: Lippincott Williams & Wilkins, 2002;206-207.
36. Conry JA, Ng YT, Paolicchi JM, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia 2009;50:1158-1166.
37. Ng YT, Conry JA, Drummond R, et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology 2011;77:1473-1481.
38. Conry JA, Ng YT, Kernitsky L, et al. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Epilepsia 2014;55:558-567.
39. Cramer JA, Sapin C, François C. Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome. Acta Neurol Scand 2013;128:91-99.
40. VanStraten AF, Ng YT. Update on the management of Lennox-Gastaut syndrome. Pediatr Neurol 2012;47:153-161.
41. Arya R, Anand V, Garg SK, Michael BD. Clobazam monotherapy for partial-onset or generalized-onset seizures. Cochrane Database Syst Rev 2014;10:CD009258.
42. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Canadian Study Group for Childhood Epilepsy. Epilepsia 1998;39:952-959.
43. Bawden HN, Camfield CS, Camfield PR, et al. The cognitive and behavioural effects of clobazam and standard monotherapy are comparable. Canadian Study Group for Childhood Epilepsy. Epilepsy Res 1999;33:133-143.
44. Dulac O, Figueroa D, Rey E, Arthuis M. Monotherapy with clobazam in epilepsies in children. Presse Med 1983;12:1067-1069.
45. Mehndiratta MM, Krishnamurthy M, Rajesh KN, Singh G. Clobazam monotherapy in drug naïve adult patients with epilepsy. Seizure 2003;12:226-228.
46. Rickels K, Brown AS, Cohen D, et al. Clobazam and diazepam in anxiety. Clin Pharmacol Ther 1981;30:95-100.
47. Jacobson AF, Goldstein BJ, Dominguez RA, Steinbook RM. A placebo-controlled, double-blind comparison of clobazam and diazepam in the treatment of anxiety. J Clin Psychiatry 1983;44:296-300.
48. Lemoine P, Rouillon F, Pouget D. Efficacy and withdrawal of clobazam, lorazepam and buspirone in the treatment of anxiety disorders. Encephale 1996;22:461-467.
49. Robertson MM. Current status of the 1, 4- and 1, 5-benzodiazepines in the treatment of epilepsy: The place of clobazam. Epilepsia 1986;27(Suppl 1):S27-S41.
50. Clobazam in treatment of refractory epilepsy: The Canadian experience. A retrospective study. Canadian Clobazam Cooperative Group. Epilepsia 1991;32:407-416.
51. Singh A, Guberman AH, Boisvert D. Clobazam in long-term epilepsy treatment: Sustained responders versus those developing tolerance. Epilepsia 1995;36:798-803.
52. Sugai K. Clobazam as a new antiepileptic drug and clorazepate dipotassium as an alternative antiepileptic drug in Japan. Epilepsia 2004;45(Suppl 8):20-25.
53. Feely M, Gibson J. Intermittent clobazam for catamenial epilepsy: Tolerance avoided. J Neurol Neurosurg Psychiatry 1984;47:1279-1282.
54. Remy C. Clobazam in the treatment of epilepsy: A review of the literature. Epilepsia 1994;35(Suppl 5):S88-S91.
55. Shimizu H, Kawasaki J, Yuasa S, et al. Use of clobazam for the treatment of refractory complex partial seizures. Seizure 2003;12:282-286.
56. Wildin JD, Pleuvry BJ, Mawer GE, et al. Respiratory and sedative effects of clobazam and clonazepam in volunteers. Br J Clin Pharmacol 1990;29:169-177.
57. Klehm J, Thome-Souza S, Sánchez Fernández I, et al. Clobazam: Effect on frequency of seizures and safety profile in different subgroups of children with epilepsy. Pediatr Neurol 2014;51:60-66.
58. Redondo P, Vicente J, España A, et al. Photo-induced toxic epidermal necrolysis caused by clobazam. Br J Dermatol 1996;135:999-1002.
59. Ertam I, Sezgin AO, Unal I. A case with Stevens Johnson syndrome triggered by combination of clobazam, lamotrigine, and valproic acid treatment. Int J Dermatol 2009;48:98-99.
60. FDA U.S. Food and Drug Administration [Internet]. FDA Drug Safety Communication: FDA warns of serious skin reactions with the anti-seizure drug Onfi (clobazam) and has approved label changes; 2013 [cited 2014 October 18]. Available from: www.fda.gov.
61. Tolbert D, Harris SI, Bekersky I, et al. Withdrawal-related adverse events from clinical trials of clobazam in Lennox-Gastaut syndrome. Epilepsy Behav 2014;37:11-15.